Endpoints in phase II trials for advanced non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

Endpoints in phase II trials for advanced non-small cell lung cancer.

Endpoints in phase II trials for advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q33557040

about

Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.Circulating tumour cells: their utility in cancer management and predicting outcomes.A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus.The power of phase II end-points for different possible mechanisms of action of an experimental treatment Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan.The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement.Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.Survival analyses in lung cancer.Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.

P2860

Q30754691-83072DEB-B8C8-4B98-8586-C7DE50965734 Q34512144-1DCDB4AC-FD5C-4A2B-ABE7-CA8F869B8459 Q35076325-B9EAA0AD-C32D-4D42-9DBA-5EE0E2C42A5F Q35093484-E28D52DF-EB96-4708-9115-9BFA1BF83847 Q35619065-CBEE7A3C-54BF-411F-9319-8E327B750BC5 Q36738554-57B36F8C-FF1C-454B-B000-CC98EEFB0BA5 Q37693477-0A2C1C24-4A83-4266-A753-CCDDFE423965 Q37698439-572C1053-2B16-4902-A935-1EDE3BB8DC26 Q38259501-CDE109A4-4B62-4B39-A12E-CCBE4D0B3973 Q38389980-2C031208-35E8-48BC-BFE7-8A1EB976CB4C Q38730533-2DEAB15D-8514-45B4-9E44-25DA17DC943D Q38746330-AF6F61EE-8609-4E04-BEA5-E53E94C74494 Q39816573-D0389527-A33B-46A0-99B8-282DBD62794F Q40595362-C64F3033-D6A3-4AF5-A83F-BFE44DFC8140 Q41962742-E43B748E-176C-43B1-8550-97496BCD6663 Q42344282-8B19E321-7E58-49ED-AB79-291DB79F8CC4 Q43754852-6F749F5B-F199-4A75-AD0A-58988176AE56 Q45718951-175F72E8-8DCB-430A-B4E5-E6C13E46208F Q53717818-ED2E6ADC-71DC-49DB-9440-9BA6102DF3D4

P2860

Endpoints in phase II trials for advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q33557040

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Endpoints in phase II trials for advanced non-small cell lung cancer.

@ast

Endpoints in phase II trials for advanced non-small cell lung cancer.

@en

Endpoints in phase II trials for advanced non-small cell lung cancer.

@nl

type

label

Endpoints in phase II trials for advanced non-small cell lung cancer.

@ast

Endpoints in phase II trials for advanced non-small cell lung cancer.

@en

Endpoints in phase II trials for advanced non-small cell lung cancer.

@nl

prefLabel

Endpoints in phase II trials for advanced non-small cell lung cancer.

@ast

Endpoints in phase II trials for advanced non-small cell lung cancer.

@en

Endpoints in phase II trials for advanced non-small cell lung cancer.

@nl

P1433

Q33557040-6BBEC892-FF3A-473F-A04F-B6A8EA136859

P1476

Q33557040-6791F08D-CD3A-416C-8A4F-07FCAFD52933

P2093

Q33557040-12129BEC-BA32-4DA1-805E-902FFD17F6B9

Q33557040-1F81A088-29C5-4C50-A805-57D6D414F403

Q33557040-2D662017-306B-48C4-A6CE-42BA9BEA0AD7

Q33557040-6394BFE1-A154-4098-AE7D-5B065C683A6C

Q33557040-86E2236D-DAE1-4A56-88BF-CB1A3CFF5236

Q33557040-9289ECE6-922F-40D5-B09A-F8910646F7A7

Q33557040-CA666415-F907-40CF-AF50-5784909F7A87

Q33557040-D4C52300-8278-462B-BA01-8AE4A7729A1D

Q33557040-E9BB22EB-B72C-4AA7-8ADC-E48A0C5677FE

P2860

Q33557040-011AA7AC-8092-41BC-AF9E-590A9C562F03

Q33557040-034EC3BF-9D40-4901-B2CE-4CCEBDC3A4F6

Q33557040-1802ACE3-26A7-4E62-A55A-C1D6DA1D6CD1

Q33557040-2767003A-98E9-4969-9119-E0DC72923916

Q33557040-4036D3FA-E00E-4A1D-8585-6B52EF48373C

Q33557040-87E79EC0-9F0B-4582-BD48-21347AE84D32

Q33557040-8D05DDEF-F74B-48AE-9600-CD6408282D4F

Q33557040-9508FCC0-6F23-46EE-ACB5-1BE532589BC3

Q33557040-9F17C707-1445-44E0-89C9-DEE6C711BE9F

Q33557040-9FB7E1FD-EE8C-4F8F-8BA3-FD059A961F74

P304

Q33557040-FC4F9362-FA7E-41A7-8AA9-205C092C4015

P31

Q33557040-43991666-7519-4CBF-8573-285763AD24B3

P356

Q33557040-E7436043-0880-4D44-ACD8-F732415168F3

P433

Q33557040-45DC287B-495D-431C-B674-1EE315AE5977

P478

Q33557040-746E6129-71BC-443B-A59A-8BBC2A07E319

P50

Q33557040-3DB751DD-F468-4951-B90F-DDBB1F74CE3C

P577

Q33557040-3BAF68DD-84CE-483A-93F0-CEAD9D9C95A2

P5875

Q33557040-9D2E3E5E-2D9F-49C4-AB48-C01047E78F1C

P698

Q33557040-0C1E54CA-F111-417C-B2FC-D1424FC66AA2

P921

Q33557040-60CAE304-4140-4928-9776-11B8C3C29BC8

P932

Q33557040-9FB8E8E1-7906-4C2A-979A-B2FE8C2E75AB

P356

JTO.0B013E3181C0A313

P1433

Journal of Thoracic Oncology

P1476

Endpoints in phase II trials for advanced non-small cell lung cancer.

@en

P2093

Alex A Adjei

http://www.w3.org/2001/XMLSchema#string

Katie L Allen Ziegler

http://www.w3.org/2001/XMLSchema#string

Kendrith M Rowland

http://www.w3.org/2001/XMLSchema#string

Nicholas F Reuter

http://www.w3.org/2001/XMLSchema#string

Randolph S Marks

http://www.w3.org/2001/XMLSchema#string

Shauna L Hillman

http://www.w3.org/2001/XMLSchema#string

Steven A Kuross

http://www.w3.org/2001/XMLSchema#string

Sumithra J Mandrekar

http://www.w3.org/2001/XMLSchema#string

Yingwei Qi

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

Regression modelling strategies for improved prognostic prediction.

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

P304

3-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0B013E3181C0A313

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Steven E Schild

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38062927

http://www.w3.org/2001/XMLSchema#string

P698

19884856

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2798014

http://www.w3.org/2001/XMLSchema#string